Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines-Reference-Cited by-同舟云学术

Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines

Published:2017-09-22 Issue:1 Volume:22 Page:568-575
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J. Cell. Mol. Med.

Author:

Schönberger Stefan¹^ORCID,van Beekum Cornelius¹,Götz Barbara¹,Nettersheim Daniel²^ORCID,Schorle Hubert²,Schneider Dominik T.³,Casati Anna¹,Craveiro Rogerio B.¹,Calaminus Gabriele¹,Dilloo Dagmar¹

Affiliation:

1. Department of Paediatric Haematology and Oncology; University Children's Hospital Bonn; University of Bonn Medical School; Bonn Germany

2. Department of Developmental Pathology; Institute of Pathology; University of Bonn Medical School; Bonn Germany

3. Clinic of Paediatrics; Municipal Hospital Dortmund; Dortmund Germany

Funder

Barbara and Hubertus Trettner foundation

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcmm.13344/fullpdf

Reference32 articles.

1. Genome-wide expression profiling reveals new insights into pathogenesis and progression of testicular germ cell tumors;Biermann;Cancer Genomics Proteomics,2007

2. Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas;Gopalan;Mod Pathol,2009

3. Guidelines on testicular cancer: 2015 update;Albers;Eur Urol,2015

4. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature;Calabro;Eur Urol,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates as a novel therapeutic modality to treat recurrent refractory germ cell tumors;American Journal of Physiology-Cell Physiology;2024-08-01

2. Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy;Pharmaceutics;2023-07-26

3. Graft-versus-host disease: Therapeutic prospects of improving the long-term post-transplant outcomes;Transplantation Reports;2022-12

4. Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin;PharmacoEconomics - Open;2022-09-04

5. Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma;Hematological Oncology;2022-07-14